Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6195263 | 0.87 | SIRT2 (0.45) | PNMTADRA2ASIRT2CYP1A2CYP2D6 | |
| SCHEMBL7456470 | 0.86 | PNMT (0.56) | PNMTADRA2ASIRT2CYP1A2CYP2D6 | |
| SCHEMBL27470339 | 0.86 | PNMT (0.64) | PNMTADRA2ASIRT2ADRA2BADRA2C | |
| SCHEMBL2776754 | 0.81 | PNMT (0.42) | PNMTADRA2ASIRT2CYP1A2CYP2D6 | |
| SCHEMBL2778779 | 0.80 | PNMT (0.46) | PNMTADRA2ASIRT2CYP1A2CYP2D6 | |
| SCHEMBL2857664 | 0.78 | ALDH1A1 (0.52) | PNMTADRA2ASIRT2ADRA2BADRA2C | |
| SCHEMBL10270869 | 0.78 | SIRT2 (0.47) | PNMTADRA2ASIRT2ADRA2BADRA2C | |
| SCHEMBL6192228 | 0.76 | PNMT (0.50) | PNMTADRA2ACYP1A2CYP2D6ADRA2B | |
| SCHEMBL27799204 | 0.76 | SIRT2 (0.45) | PNMTADRA2ASIRT2ADRA2BADRA2C | |
| SCHEMBL8238979 | 0.75 | TRPM5 (0.43) | CYP1A2CYP2D6SLC6A4DRD3OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | disclosed |
| CN-1564820-A | Heterocyclic compounds for use in the treatment of disorders of the urinary tract | RECORDATI CHEM PHARM (CH) | 2005-01-12 | — | — | CN | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | PNMT 251/4885ADRA2A 48/4885SIRT2 2319/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | PNMT 186/4885ADRA2A 30/4885SIRT2 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.